For the quarter ended December 2025, Zai Lab Limited Unsponsored ADR (ZLAB) reported revenue of $127.6 million, up 17% over the same period last year. EPS came in at -$0.46, compared to -$0.80 in the year-ago quarter.
The reported revenue represents a surprise of +6.85% over the Zacks Consensus Estimate of $119.42 million. With the consensus EPS estimate being -$0.44, the EPS surprise was -4.55%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Zai Lab Limited performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product Revenue, net: $127.09 million compared to the $132.11 million average estimate based on three analysts.
- Product Revenue- XACDURO: $10.7 million versus the two-analyst average estimate of $9.6 million.
- Product Revenue- VYVGART: $21.9 million compared to the $39.74 million average estimate based on two analysts. The reported number represents a change of -27% year over year.
- Product Revenue- NUZYRA: $16 million versus $17.22 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +45.5% change.
- Collaboration revenue: $0.51 million compared to the $19.34 million average estimate based on two analysts.
- Product Revenue- ZEJULA: $56 million versus the two-analyst average estimate of $49.17 million. The reported number represents a year-over-year change of +15.7%.
View all Key Company Metrics for Zai Lab Limited here>>>
Shares of Zai Lab Limited have returned +12.7% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
